Want to see HK:0399 full AI Analyst Report?
0399 Stock Chart & Stats
HK$0.09
>-HK$0.01(-3.77%)
At close: 4:00 PM EST
HK$0.09
>-HK$0.01(-3.77%)
Day’s Range― - ―
52-Week RangeHK$0.05 - HK$0.73
Previous CloseN/A
Volume1.53M
Average Volume (3M)17.09M
Market Cap
HK$231.21M
Enterprise ValueHK$1.24B
Total Cash (Recent Filing)HK$18.07M
Total Debt (Recent Filing)HK$1.09B
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Nov 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding3,167,207,000
10 Day Avg. Volume17,323,689
30 Day Avg. Volume17,085,593
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.44
Price to Sales (P/S)143.85
P/FCF Ratio-28.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Cash Flow TrendReported improvement in cash burn and positive free cash flow growth in the latest year suggests the business may be moving toward self-funding or at least reduced external funding needs. If sustained, this improves durability of operations and reduces refinancing pressure over the medium term.
Historic Profitable EpisodesThe firm has produced profit in prior years (notably 2022 and 2024), indicating the underlying business can reach positive margins. These episodes show operational levers and demand elasticity that, if management restores revenue stability, could enable durable margin recovery and cash generation.
Lean Operating FootprintA very small headcount implies a lean cost base and lower fixed overhead, improving flexibility to scale down or pivot with limited restructuring friction. Combined with low beta, this suggests lower equity volatility and potential for steadier operating adjustments across cycles.
Bears Say
Negative Shareholders' EquityPersistently negative equity is a structural solvency concern that constrains financing options, raises bankruptcy or restructuring risk, and can trigger lender covenants. This materially weakens long-term capital stability and limits capacity to absorb losses or fund growth without dilution.
Large, Persistent Debt BurdenA sizeable and persistent debt load relative to the capital base increases interest and refinancing risk, especially given negative equity and uneven cash flows. Over the medium term, high leverage can force asset sales, costly refinancing, or covenant-driven restructurings that impair strategic options.
Multi-year Revenue Decline And Volatile ProfitabilitySustained revenue erosion and a sharp ~53% decline in 2025 undermine scale economics and make margins volatile (gross margins thin at ~9–13%). Structural revenue weakness limits ability to rebuild profitability and makes long-term recovery dependent on meaningful, durable top-line improvements.
Innovative Pharmaceutical Biotech News
0399 FAQ
What was Innovative Pharmaceutical Biotech Limited’s price range in the past 12 months?
Innovative Pharmaceutical Biotech Limited lowest stock price was HK$0.05 and its highest was HK$0.73 in the past 12 months.
What is Innovative Pharmaceutical Biotech Limited’s market cap?
Innovative Pharmaceutical Biotech Limited’s market cap is HK$231.21M.
When is Innovative Pharmaceutical Biotech Limited’s upcoming earnings report date?
Innovative Pharmaceutical Biotech Limited’s upcoming earnings report date is Nov 27, 2026 which is in 145 days.
How were Innovative Pharmaceutical Biotech Limited’s earnings last quarter?
Currently, no data Available
Is Innovative Pharmaceutical Biotech Limited overvalued?
According to Wall Street analysts Innovative Pharmaceutical Biotech Limited’s price is currently Overvalued.
Does Innovative Pharmaceutical Biotech Limited pay dividends?
Innovative Pharmaceutical Biotech Limited does not currently pay dividends.
What is Innovative Pharmaceutical Biotech Limited’s EPS estimate?
Innovative Pharmaceutical Biotech Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Innovative Pharmaceutical Biotech Limited have?
Innovative Pharmaceutical Biotech Limited has 3,167,207,000 shares outstanding.
What happened to Innovative Pharmaceutical Biotech Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Innovative Pharmaceutical Biotech Limited?
Currently, no hedge funds are holding shares in HK:0399
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innovative Pharmaceutical Biotech Stock Smart Score
Company Description
Innovative Pharmaceutical Biotech Limited
Operating as an investment holding company, Innovative Pharmaceutical Biotech Limited (IPBL) primarily engages in the distribution of beauty equipment and associated products across both mainland China and Hong Kong. The firm structures its operations into two key divisions: Trading of Beauty Products and Research and Development. Furthermore, IPBL's diversified activities include securities investments, the development and market introduction of oral insulin products, the provision of bio-industrial goods, and offering genetic screening services. The company rebranded to Innovative Pharmaceutical Biotech Limited in September 2015, having previously been known as United Gene High-Tech Group Limited. Its principal office is located in Sheung Wan, Hong Kong.
Technical Analysis
Natural Beauty Bio-Technology
―
Cheerwin Group Limited
―
Dingdang Health Technology Group Ltd.
―
Giant Biogene Holding Co. Ltd.
―
Nanjing Sinolife United Co., Ltd. Class H
―
Options Prices
Currently, No data available
---